This site is intended for healthcare professionals
Drug information


Read time: 11 mins
Last updated: 06 May 2020
Published: 01 Apr 2021

4.1 Therapeutic indications



Fluticasone propionate cream is a potent topical corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses; these include the following:

• Atopic dermatitis

• Nummular dermatitis (discoid eczemas)

• Prurigo nodularis

• Psoriasis (excluding widespread plaque psoriasis)

• Lichen simplex chronicus (neurodermatitis) and lichen planus

• Seborrhoeic dermatitis

• Irritant or allergic contact dermatitis

• Discoid lupus erythematosus

• An adjunct to systemic steroid therapy in generalised erythroderma

• Insect bite reactions

• Miliaria (prickly heat)


For children and infants aged three months and over who are unresponsive to lower potency corticosteroids, Cutivate cream is indicated for the relief of the inflammatory and pruritic manifestations of atopic dermatitis under the supervision of a specialist. Expert opinion should be sought prior to the use of Cutivate cream in other corticosteroid-responsive dermatoses in children.

Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.




The drug SPC information (indications, contra-indications, interactions, etc), has been developed in collaboration with eMC ( Medthority offers the whole library of SPC documents from eMC.

Medthority will not be held liable for explicit or implicit errors, or missing data.

Reporting of suspected adverse reactions 

Drug Licencing

Drugs appearing in this section are approved by UK Medicines & Healthcare Products Regulatory Agency (MHRA), & the European Medicines Agency (EMA).